Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT ID: NCT00105547
Last Updated: 2009-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1600 participants
INTERVENTIONAL
2005-02-28
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00322036
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
NCT00566397
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective of the study is to evaluate the change in cognition and activities of daily living.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
800 mg BID
MPC-7869
oral 800 mg BID
2
BID dosing
MPC-7869
Oral BID dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MPC-7869
oral 800 mg BID
MPC-7869
Oral BID dosing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
* Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
* Ability to read and understand English or Spanish to ensure compliance with cognitive testing and study visit procedures.
* Female subjects must be surgically sterile or postmenopausal for \> 1 year.
* Subjects currently taking approved medication for Alzheimer's disease for at least six months prior to day 1 may be enrolled.
* Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.
Exclusion Criteria
* History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
* Chronic or acute renal, hepatic or metabolic disorder.
* Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
* Major surgery and related complications not resolved within 12 weeks prior to Day 1.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Myrexis Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myriad Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ed Swabb, MD
Role: STUDY_DIRECTOR
Myrexis Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabaster, Alabama, United States
Huntsville, Alabama, United States
Mesa, Arizona, United States
Peoria, Arizona, United States
Phoenix, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Fresno, California, United States
Irvine, California, United States
La Jolla, California, United States
Lafayette, California, United States
Laguna Hills, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Newport Beach, California, United States
Oceanside, California, United States
Rancho Mirage, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
San Francisco, California, United States
Vista, California, United States
Denver, Colorado, United States
Danbury, Connecticut, United States
Darien, Connecticut, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Bay Harbor, Florida, United States
Boca Raton, Florida, United States
Clearwater, Florida, United States
Derrfield Beach, Florida, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Fort Myers, Florida, United States
Hialeah, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
North Miami, Florida, United States
Ocala, Florida, United States
Orlando, Florida, United States
Plantation, Florida, United States
Pompano Beach, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Chicago, Illinois, United States
Fort Wayne, Indiana, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Glen Burnie, Maryland, United States
Boston, Massachusetts, United States
Brockton, Massachusetts, United States
West Yarmouth, Massachusetts, United States
Farmington Hills, Michigan, United States
Grand Rapids, Michigan, United States
Rochester, Minnesota, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Lebanon, New Hampshire, United States
Kenilworth, New Jersey, United States
Morristown, New Jersey, United States
Piscataway, New Jersey, United States
Princeton, New Jersey, United States
Stratford, New Jersey, United States
Toms River, New Jersey, United States
Albuquerque, New Mexico, United States
Albany, New York, United States
Brooklyn, New York, United States
Brooklyn, New York, United States
Elmsford, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Olean, New York, United States
Rochester, New York, United States
Syracuse, New York, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Winston-Salem, North Carolina, United States
Centerville, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Eugene, Oregon, United States
Portland, Oregon, United States
Portland, Oregon, United States
Bala-Cynwyd, Pennsylvania, United States
Jenkintown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Scotland, Pennsylvania, United States
East Providence, Rhode Island, United States
East Providence, Rhode Island, United States
Providence, Rhode Island, United States
Beaufort, South Carolina, United States
Greer, South Carolina, United States
North Charleston, South Carolina, United States
Johnson City, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Austin, Texas, United States
Dallas, Texas, United States
Galveston, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Wichita Falls, Texas, United States
Ogden, Utah, United States
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
Bennington, Vermont, United States
Alexandria, Virginia, United States
Charlottesville, Virginia, United States
Virginia Beach, Virginia, United States
Middleton, Wisconsin, United States
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPC-7869-04-005.02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.